아시아 태평양 항바이러스 약물 시장 – 2030년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Pharmaceutical Asia Pacific Antiviral Drugs Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 항바이러스 약물 시장 – 2030년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • May 2023
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 654
  • 그림 수: 45
지금 구매 지금 구매

Asia Pacific Antiviral Drugs Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2024 –2030
Diagram 시장 규모(기준 연도)
 백만 달러
요구
Diagram 시장 규모(예측 연도)
 미국 달러 15,118.64
Diagram 연평균 성장률
 %
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
잠금 해제 요청

>아시아 태평양 항바이러스 약물 시장, 적응증별(인플루엔자, 인간 면역 결핍 바이러스(HIV), C형 간염 바이러스(HCV), 호흡기 세포융합 바이러스, 단순포진 바이러스, 인간 거대세포바이러스(HCMV), 수두대상포진 바이러스(VZV), B형 간염 바이러스(HBV), 코로나바이러스 감염 및 기타), 환자 유형(소아, 성인 및 노인), 제품(경구, 국소 및 비경구), 약물 유형(제네릭 및 브랜드), 최종 사용자(병원, 진료소, 재택 건강 관리, 전문 센터, 외래 센터 및 기타), 유통 채널(병원 약국, 온라인 약국 및 소매 약국) - 업계 동향 및 2030년까지의 예측.  

아시아 태평양 항바이러스 약물 시장

아시아 태평양 항바이러스 약물 시장 분석 및 통찰력

아시아 태평양 지역에서 바이러스 감염에 대한 인식이 증가함에 따라 시장 수요가 증가했습니다. 더 나은 건강 서비스를 위한 의료비 지출 증가도 시장 성장에 기여합니다. 주요 시장 참여자들은 이 중요한 기간 동안 다양한 서비스 출시와 승인에 집중합니다. 또한, 약물 개발 기술의 향상된 발전도 항바이러스 약물에 대한 수요 증가에 기여합니다.

아시아 태평양 항바이러스 약물 시장아시아 태평양 항바이러스 약물 시장

아시아 태평양 항바이러스 약물 시장은 시장 참여자의 증가와 고급 서비스의 가용성으로 인해 예측 연도에 성장할 것으로 예상됩니다. 이와 함께 제조업체는 시장에서 새로운 서비스를 출시하기 위한 개발 활동에 참여하고 있습니다. 약물 개발 분야의 개발 증가는 시장 성장을 더욱 촉진하고 있습니다. 그러나 표준화된 프로토콜의 부족과 숙련된 전문가의 부족과 같은 어려움은 예측 기간 동안 아시아 태평양 항바이러스 약물 시장의 성장을 방해할 수 있습니다.

의료 서비스 지출이 진전 및 약물 개발에 증가함에 따라 시장에 기회가 생길 것으로 예상됩니다. 그러나 대체 치료법의 사용이 증가함에 따라 시장 성장에 어려움이 있을 수 있습니다. Data Bridge Market Research는 아시아 태평양 항바이러스 약물 시장이 2030년까지 15,118.64백만 달러에 도달할 것으로 예상되며 예측 기간 동안 CAGR은 6.7%가 될 것으로 분석했습니다.  

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020까지 사용자 정의 가능)

양적 단위

매출은 백만, 볼륨은 단위, 가격은 USD로 표시

다루는 세그먼트

적응증(인플루엔자, 인간면역결핍바이러스(HIV), C형 간염바이러스(HCV), 호흡기세포융합바이러스, 단순포진바이러스, 인간거대세포바이러스(HCMV), 수두대상포진바이러스(VZV), B형 간염바이러스(HBV), 코로나바이러스감염증 및 기타), 환자 유형(소아, 성인 및 노인), 제품(경구, 국소 및 비경구), 약물 유형(제네릭 및 브랜드), 최종 사용자(병원, 진료소, 홈 헬스케어 , 전문 센터, 외래 센터 및 기타), 유통 채널(병원 약국, 온라인 약국 및 소매 약국)

적용 국가

중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남 및 아시아 태평양의 나머지 지역

시장 참여자 포함

Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, Hetero. 등

아시아 태평양 항바이러스 약물 시장 정의

항바이러스 약물은 숙주 세포 내에서 바이러스의 복제를 억제하여 바이러스 감염을 치료하는 데 사용되는 약물입니다. 이러한 약물은 특정 바이러스 또는 바이러스 유형을 표적으로 삼고 바이러스가 숙주 세포로 들어가는 것을 막거나 바이러스 복제에 필요한 주요 효소 또는 단백질을 차단하여 작동합니다. 박테리아 감염을 치료하는 데 사용되는 항생제 와 달리 항바이러스 약물은 일반적으로 효과가 떨어집니다. 바이러스는 구조가 훨씬 간단하고 복제를 위해 숙주 세포에 의존하기 때문입니다. 그러나 인플루엔자, 헤르페스, HIV 와 같은 일부 바이러스 감염을 치료하는 데 여전히 유용할 수 있습니다 .

아시아 태평양 항바이러스 약물 시장 동향

이 섹션에서는 시장 동인, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.     

운전자

  • 바이러스 감염의 유병률 증가

지난 수십 년 동안 전 세계적으로 바이러스 감염이 꾸준히 증가했습니다. 신체에 침투하여 세포를 복제하고 퍼지는 바이러스는 바이러스 감염을 일으킵니다. 바이러스 감염은 경미한 것부터 심각한 것까지 다양한 증상을 초래할 수 있으며, 어떤 경우에는 생명을 위협하는 증상도 나타날 수 있습니다. 세계화는 바이러스 감염 증가의 주요 원인 중 하나입니다. 사람들은 경계를 넘어 여행하고 서로 소통하며, 이로 인해 세상은 그 어느 때보다 더 연결되어 있습니다. 이러한 향상된 연결성으로 인해 한 지역에서 다른 지역으로의 바이러스 전파가 가속화되었습니다.

따라서 바이러스 감염의 증가하는 유행은 여러 요인이 기여하는 복잡한 문제입니다. 세계화, 인구 밀도, 기후 변화, 항생제 내성은 모두 바이러스 확산에 영향을 미칩니다. 따라서 시장 성장을 촉진할 것으로 예상됩니다.

  • 새로운 항바이러스 약물 개발의 진전

항바이러스 치료제는 바이러스 감염 환자에게 처방됩니다. 새로운 항바이러스 약물의 창조는 시간이 지남에 따라 엄청난 진전을 이루었습니다. 이러한 발전은 질병 부담을 낮추고, 바이러스 감염 치료를 개선하고, 생명을 구했습니다. 새로운 항바이러스 약물 분야에서 많은 발전이 있습니다.

따라서 새로운 항바이러스 약물 개발의 발전으로 바이러스 감염 치료가 개선되고, 질병 부담이 줄어들었으며 시장 성장이 촉진될 것으로 예상됩니다.

제지

  • 항바이러스 약물의 높은 비용

항바이러스 약물의 높은 비용은 환자와 의료 시스템에 상당한 영향을 미칠 수 있습니다. 이러한 약물을 감당할 수 없는 환자는 치료를 받지 않거나 열등한 치료에 의존하여 더 나쁜 건강 결과를 초래할 수 있습니다. 또한 항바이러스 약물의 높은 비용은 특히 자원이 제한된 국가에서 의료 예산에 부담을 줄 수 있습니다.

따라서 항바이러스 약물의 높은 비용은 아시아 태평양 항바이러스 약물 시장을 제약할 것으로 예상됩니다.

기회

  • 새로운 약물 전달 시스템의 등장

항바이러스 약물에 대한 연구는 새로운 약물 전달 메커니즘을 만드는 데 중점을 두었습니다. 기존의 약물 투여 기술에 비해 새로운 전달 시스템은 생체 이용률 개선, 맞춤형 약물 전달, 부작용 감소 등 여러 가지 이점이 있습니다.

따라서 새로운 약물 전달 시스템을 개발하는 것은 항바이러스 약물에 대한 중요한 연구 분야입니다. 나노입자 약물 전달 시스템, 하이드로젤, 덴드리머, 마이크로니들, 세포 침투 펩타이드는 항바이러스 약물에 대해 조사된 유망한 약물 전달 시스템입니다. 이러한 전달 시스템은 기존 약물 전달 방법에 비해 여러 가지 이점을 제공하며 항바이러스 약물의 효능과 안전성을 개선할 수 있는 잠재력이 있으며 시장 성장에 기회를 창출할 것으로 예상됩니다.

도전

  • 항바이러스제 특허 만료

특허 만료 프로세스는 원래 개발자 또는 특허 보유자가 특정 의약품을 생산하고 판매할 독점권을 잃는 결과를 낳습니다. 항바이러스 약물의 특허 만료는 제네릭 의약품 생산자와의 경쟁을 초래할 수 있으므로 제약 사업에 상당한 영향을 미칠 수 있습니다.

항바이러스 약물의 특허는 제작자가 약물을 제조하고 판매할 단독 권리를 가진 기간이 끝나면 만료됩니다. 약물의 특허가 만료되면 다른 생산자가 제네릭 버전을 만들어 판매할 수 있습니다. 이로 인해 경쟁이 심화되고 소비자 가격이 낮아질 수 있습니다. HIV, B형 및 C형 간염, 헤르페스, 독감 및 기타 바이러스성 질환은 모두 항바이러스 약물로 치료합니다. 항바이러스 약물의 특허는 약물과 국가에 따라 만료되는 시기가 다릅니다. 약물 특허는 일반적으로 신청일로부터 20년 동안 부여됩니다. 다른 생산자는 특허가 만료되면 제네릭 버전의 약물을 자유롭게 만들어 판매할 수 있습니다. 생산자는 마케팅, 연구 개발 및 임상 연구에 많은 비용을 지출할 필요가 없기 때문에 제네릭 약물은 종종 브랜드 약물보다 저렴합니다.

따라서 항바이러스 약물의 특허 만료는 이 중요한 약물의 가용성, 가격, 접근성에 중대한 영향을 미칠 수 있으며 시장 성장에 어려움을 겪을 것으로 예상됩니다.

최근 개발 사항

  • 2023년 1월, MSD로 알려진 Merck는 자회사를 통해 Imago Biosciences, Inc.(Nasdaq: IMGO)의 모든 유통 주식에 대한 현금 인수 제안을 성공적으로 완료했다고 발표했습니다. 인수 가격은 주당 36.00달러이며, 이자 없이 필요한 세금 원천징수에 대한 공제가 적용됩니다. 이 인수는 매출 증가에 도움이 될 것입니다.
  • 2021년 4월, Zydus Pharmaceuticals, Inc.는 인도 약물 관리자 총국(DCGI)으로부터 중증 COVID-19 감염 치료에 항바이러스제 Virafin을 사용하도록 제한적 긴급 사용 승인을 받았다고 발표했습니다. 이를 통해 회사는 아시아 태평양 지역에서의 입지를 강화하고 전 세계 다른 지역에서 명성을 쌓을 수 있을 것입니다.

아시아 태평양 항바이러스 약물 시장 범위

아시아 태평양 항바이러스 약물 시장은 적응증, 환자 유형, 제품, 약물 유형, 최종 사용자 및 유통 채널을 기준으로 6개의 주요 세그먼트로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.    

표시

  • 인플루엔자
  • 인간 면역 결핍 바이러스(HIV)
  • C형 간염 바이러스
  • 단순 포진 바이러스
  • 인간 거대세포바이러스(HCMV)
  • 수두대상포진바이러스(VZV)
  • B형 간염 바이러스
  • RS 바이러스
  • 코로나바이러스 감염
  • 기타

아시아 태평양 항바이러스 약물 시장은 적응증을 기준으로 인플루엔자, 인간 면역 결핍 바이러스(HIV), C형 간염 바이러스(HCV), 호흡기 세포융합 바이러스, 단순포진 바이러스, 인간 거대세포바이러스(HCMV), 수두대상포진 바이러스(VZV), B형 간염 바이러스(HBV), 코로나바이러스 감염 및 기타로 구분됩니다.

환자 유형

  • 어린이
  • 성인
  • 노인

아시아 태평양 항바이러스제 시장은 환자 유형을 기준으로 소아, 성인, 노인으로 구분됩니다.  

제품

  • 경구
  • 뉴스 영화
  • 비경구적

아시아 태평양 항바이러스 약물 시장은 제품을 기준으로 경구용, 국소용, 비경구용으로 구분됩니다.

약물 유형

  • 일반적인
  • 브랜드화

아시아 태평양 항바이러스 약물 시장은 약물 유형을 기준으로 제네릭과 브랜드 약물로 구분됩니다.

최종 사용자

  • 병원
  • 클리닉
  • 홈 헬스케어
  • 전문 센터
  • 외래 진료 센터
  • 기타

아시아 태평양 항바이러스제 시장은 최종 사용자를 기준으로 병원, 진료소, 가정 의료, 전문 센터, 외래 환자 센터 및 기타로 구분됩니다.

유통 채널

  • 병원 약국
  • 온라인 약국
  • 소매 약국

아시아 태평양 항바이러스제 시장은 유통 채널을 기준으로 병원 약국, 온라인 약국, 소매 약국으로 구분됩니다.

항바이러스 약물 시장

아시아 태평양 항바이러스 약물 시장 지역 분석/통찰력

아시아 태평양 항바이러스 약물 시장은 적응증, 환자 유형, 제품, 약물 유형, 최종 사용자 및 유통 채널을 기준으로 6개의 주요 부문으로 분류됩니다.

이 시장 보고서에서 다루는 국가는 중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 그리고 아시아 태평양의 나머지 지역입니다.

2023년에는 일본이 주요 기업의 강력한 입지와 신흥 시장의 수요 증가, 확장에 힘입어 아시아 태평양 지역을 장악하게 될 것입니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 아시아 태평양 항바이러스 약물 시장 점유율 분석

아시아 태평양 항바이러스 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 호흡, 적용 우세, 제품 유형 생명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 회사가 아시아 태평양 항바이러스 약물 시장에 집중하는 것과만 관련이 있습니다.   

아시아 태평양 항바이러스 약물 시장에서 활동하는 주요 기업으로는 Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, Hetero 등이 있습니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

7 REGULATORY FRAMEWORK

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS

8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT

8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES

8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES

8.2 RESTRAINS

8.2.1 HIGH COST OF ANTIVIRAL DRUGS

8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES

8.3 OPPORTUNITIES

8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS

8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS

8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES

8.4 CHALLENGES

8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS

8.4.2 DEMAND FOR ALTERNATIVE MEDICINES

9 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION

9.1 OVERVIEW

9.2 INFLUENZA

9.2.1 NEURAMINIDASE INHIBITORS

9.2.1.1 OSELTAMIVIR

9.2.1.2 ZANAMIVIR

9.2.1.3 PERAMIVIR

9.2.1.4 LANINAMIVIR

9.2.2 M2 INHIBITORS

9.2.2.1 RIMANTADINE

9.2.2.2 OTHERS

9.2.3 RNA POLYMERASE INHIBITORS

9.2.3.1 FAVIPIRAVIR

9.2.3.2 BALOXAVIR MARBOXIL

9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)

9.3.1 REVERSE TRANSCRIPTASE INHIBITORS

9.3.1.1 NUCLEOSIDE (NRTIS)

9.3.1.1.1 LAMIVUDINE

9.3.1.1.2 ABACAVIR

9.3.1.1.3 DIDANOSINE

9.3.1.1.4 OTHERS

9.3.1.2 NONNUCLEOSIDE (NNRTIS)

9.3.1.2.1 EFAVIRENZ

9.3.1.2.2 NEVIRAPINE

9.3.1.2.3 DELAVIRDINE

9.3.1.2.4 OTHERS

 

9.3.1.3 INTEGRASE

9.3.1.3.1 DOLUTEGRAVIR

9.3.1.3.2 ELVITEGRAVIR

9.3.1.3.3 RALTEGRAVIR

9.3.1.3.4 BICTEGRAVIR

9.3.1.4 NUCLEOTIDE

9.3.1.4.1 TENOFOVIR

9.3.1.4.2 OTHERS

9.3.1.5 INTERFERONS

9.3.1.5.1 ALPHA

9.3.1.5.2 BETA

9.3.1.5.3 GAMMA

9.3.1.6 GP41

9.3.1.6.1 ENFUVIRTIDE

9.3.1.6.2 OTHERS

9.3.2 PROTEASE

9.3.2.1 ATAZANAVIR

9.3.2.2 DARUNAVIR

9.3.2.3 LOPINAVIR

9.3.2.4 RITONAVIR

9.3.2.5 SAQUINAVIR

9.3.2.6 INDINAVIR

9.3.2.7 NELFINAVIR

9.3.2.8 TIPRANAVIR

9.3.2.9 AMPRENAVIR

9.4 HEPATITIS C VIRUS

9.4.1 NS5B POLYMERASE

9.4.1.1 SOFOSBUVIR

9.4.1.2 DASABUVIR

9.4.2 NS3/4A PROTEASE

9.4.2.1 DANOPREVIR

9.4.2.2 GLECAPREVIR

9.4.2.3 GRAZOPREVIR

9.4.2.4 PARITAPREVIR

9.4.2.5 SIMEPREVIR

 

9.4.3 NS5A PHOSPHOPROTEIN

9.4.3.1 LEDIPASVIR

9.4.3.2 VELPATASVIR

9.4.3.3 OMBITASVIR

9.4.3.4 ELBASVIR

9.4.3.5 DACLATASVIR

9.4.3.6 PIBRENTASVIR

9.4.4 NEURAMINIDASE

9.4.4.1 OSELTAMIVIR

9.4.4.2 ZANAMIVIR

9.4.4.3 PERAMIVIR

9.4.4.4 LANINAMIVIR

9.4.5 RNA POLYMERASE

9.4.5.1 BALOXAVIR MARBOXIL

9.4.5.2 FAVIPIRAVIR

9.4.6 MATRIX PROTEIN 2

9.4.6.1 RIMATIDINE

9.4.6.2 FAVIPIRAVIR

9.5 HERPES SIMPLEX VIRUS

9.5.1 DNA POLYMERASE UL30

9.5.1.1 ACICLOVIR

9.5.1.2 FAMCICLOVIR

9.5.1.3 VALACICLOVIR

9.5.1.4 PENCICLOVIR TRIFLURIDINE

9.5.1.5 BRIVUDINE

9.5.1.6 FOSCARNET

9.5.1.7 IDOXURIDINE

9.5.2 ENVELOPE PROTEINS

9.5.2.1 DOCOSANOL

9.5.2.2 OTHERS

9.6 HUMAN CYTOMEGALOVIRUS (HCMV)

9.6.1 GANCICLOVIR

9.6.2 VALGANCICLOVIR

9.6.3 CIDOFOVIR

9.6.4 FOSCARNET

9.6.5 FOMIVIRSEN

 

9.7 VARICELLA-ZOSTER VIRUS (VZV)

9.7.1 VALACICLOVIR

9.7.2 FAMCICLOVIR

9.7.3 ACICLOVIR

9.7.4 VIDARABINE

9.7.5 BRIVUDINE

9.8 HEPATITIS B VIRUS

9.8.1 ENTECAVIR

9.8.2 TENOFOVIR

9.8.3 TELBIVUDINE

9.8.4 TENOFOVIR ALAFENAMIDE

9.8.5 OTHERS

9.9 RESPIRATORY SYNCYTIAL VIRUS

9.9.1 RNA POLYMERASE

9.9.1.1 RIBAVIRIN

9.9.1.2 OTHERS

9.9.2 FUSION GLYCOPROTEIN

9.9.2.1 PALIVIZUMAB

9.9.2.2 OTHERS

9.1 CORONAVIRUS INFECTION

9.11 OTHERS

10 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 GERIATRIC

10.2.1 MALE

10.2.2 FEMALE

10.3 CHILD

10.3.1 MALE

10.3.2 FEMALE

10.4 ADULT

10.4.1 MALE

10.4.2 FEMALE

 

11 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS

11.1 OVERVIEW

11.2 ORAL

11.2.1 SOLID

11.2.1.1 TABLETS

11.2.1.2 CAPSULES

11.2.1.3 OTHERS

11.2.2 SEMISOLID

11.2.2.1 GELS

11.2.2.2 EMULSIONS

11.2.2.3 ELIXIRS

11.2.2.4 OTHERS

11.2.3 LIQUID

11.2.3.1 SOLUTIONS

11.2.3.2 SYRUPS

11.2.3.3 OTHERS

11.3 TOPICAL

11.3.1 SEMI-SOLID

11.3.1.1 CREAM

11.3.1.2 OINTMENT

11.3.1.3 GELS

11.3.1.4 OTHERS

11.3.2 LIQUID

11.3.2.1 SOLUTIONS

11.3.2.2 SUSPENSIONS

11.3.3 SOLID

11.3.3.1 POWDERS

11.3.3.2 SUPPOSITORIES

11.3.3.3 ENEMA

11.3.3.4 OTHERS

11.4 PARENTERAL

11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS

11.4.1.1 SOLUTIONS

11.4.1.2 RECONSTITUTED/LYOPHILIZED

11.4.1.3 SUSPENSIONS

11.4.1.4 EMULSIONS

11.4.1.5 OTHERS

11.4.2 NOVEL DRUG DELIVERY FORMULATIONS

11.4.3 COLLOIDAL DISPERSIONS

11.4.4 LONG ACTING INJECTION FORMULATION

12 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

13 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 SPECIALTY CENTERS

13.4 AMBULATORY CENTRES

13.5 CLINICS

13.6 HOME HEALTHCARE

13.7 OTHERS

14 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 ONLINE PHARMACY

15 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 JAPAN

15.1.2 CHINA

15.1.3 SOUTH KOREA

15.1.4 INDIA

15.1.5 AUSTRALIA

15.1.6 SINGAPORE

15.1.7 THAILAND

15.1.8 MALAYSIA

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

 

18 COMPANY PROFILE

18.1 GILEAD SCIENCES, INC. (2022)

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 PFIZER INC. (2022)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 SIGA TECHNOLOGIES (2022)

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 GLAXOSMITHKLINE PLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 F. HOFFMANN-LA ROCHE LTD. (2022)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBVIE INC.

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

 

18.7 AUROBINDO PHARMA (2022)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 AVET PHARMACEUTICALS INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 BRISTOLL MYERS SQUIBB (2022)

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 BIOCRYST PHARMACEUTICALS, INC. (2022)

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 CIPLA INC. (2022)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 DR. REDDY’S LABORATORIES LTD. (2022)

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 EMERGENT (2022)

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 HETERO.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

 

18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 MACLEODS PHARMACEUTICALS LTD.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MERCK & CO., INC, (2022)

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022)

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 NAVINTA LLC.

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022)

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022)

18.21.1 COMPANY SNAPSHOT

18.21.2 REVENUE ANALYSIS

18.21.3 PRODUCT PORTFOLIO

18.21.4 RECENT DEVELOPMENT

18.22 ZYDUS PHARMACEUTICALS, INC. (2022)

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENTS

 

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 2 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 5 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 10 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 12 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 14 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 15 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 16 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 17 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 19 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 20 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 22 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 23 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 24 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 25 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 27 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 28 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 31 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)

TABLE 42 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 61 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 63 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 68 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 74 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 75 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 76 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 77 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 78 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 79 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 80 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 81 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 82 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 83 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 84 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 86 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 87 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 88 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 89 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 90 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 91 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 92 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 93 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 94 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 95 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 96 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 97 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 98 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 99 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 100 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 101 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 102 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 103 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 104 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 105 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 106 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 107 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 108 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 109 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 110 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 111 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 112 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 113 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 114 JAPAN ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 115 JAPAN INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 116 JAPAN NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 117 JAPAN M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 118 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 119 JAPAN HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 120 JAPAN REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 121 JAPAN NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 122 JAPAN NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 123 JAPAN INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 124 JAPAN NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 125 JAPAN INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 126 JAPAN GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 127 JAPAN PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 128 JAPAN HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 129 JAPAN NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 130 JAPAN NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 131 JAPAN NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 132 JAPAN NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 133 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 134 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 135 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 136 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 137 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 138 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 139 JAPAN ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 140 JAPAN HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 141 JAPAN VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 142 JAPAN DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 143 JAPAN RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 144 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 145 JAPAN FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 146 JAPAN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 147 JAPAN GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 148 JAPAN CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 149 JAPAN ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 150 JAPAN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 151 JAPAN ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 152 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 153 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 154 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 155 JAPAN TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 156 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 157 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 158 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 159 JAPAN PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 160 JAPAN CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 161 JAPAN NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 162 JAPAN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 163 JAPAN ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 164 JAPAN ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 165 CHINA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 166 CHINA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 167 CHINA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 168 CHINA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 169 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 170 CHINA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 171 CHINA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 172 CHINA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 173 CHINA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 174 CHINA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 175 CHINA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 176 CHINA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 177 CHINA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 178 CHINA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 179 CHINA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 180 CHINA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 181 CHINA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 182 CHINA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 183 CHINA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 184 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 185 CHINA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 186 CHINA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 187 CHINA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 188 CHINA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 189 CHINA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 190 CHINA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 191 CHINA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 192 CHINA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 193 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 194 CHINA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 195 CHINA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 196 CHINA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 197 CHINA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 198 CHINA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 199 CHINA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 200 CHINA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 201 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 202 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 203 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 204 CHINA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 205 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 206 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 207 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 208 CHINA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 209 CHINA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 210 CHINA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 211 CHINA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 212 CHINA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 CHINA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 215 SOUTH KOREA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 216 SOUTH KOREA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 217 SOUTH KOREA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 218 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 219 SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 220 SOUTH KOREA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 221 SOUTH KOREA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 222 SOUTH KOREA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 223 SOUTH KOREA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 224 SOUTH KOREA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 225 SOUTH KOREA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 226 SOUTH KOREA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 227 SOUTH KOREA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 228 SOUTH KOREA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 229 SOUTH KOREA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 230 SOUTH KOREA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 231 SOUTH KOREA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 232 SOUTH KOREA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 233 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 234 SOUTH KOREA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 235 SOUTH KOREA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 236 SOUTH KOREA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 237 SOUTH KOREA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 238 SOUTH KOREA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 239 SOUTH KOREA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 240 SOUTH KOREA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 241 SOUTH KOREA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 242 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 243 SOUTH KOREA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 244 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 245 SOUTH KOREA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 246 SOUTH KOREA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 247 SOUTH KOREA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 248 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 249 SOUTH KOREA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 250 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 251 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 252 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 253 SOUTH KOREA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 254 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 255 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 256 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 257 SOUTH KOREA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 258 SOUTH KOREA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 259 SOUTH KOREA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 260 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 261 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 262 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 263 INDIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 264 INDIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 265 INDIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 266 INDIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 267 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 268 INDIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 269 INDIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 270 INDIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 271 INDIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 272 INDIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 273 INDIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 274 INDIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 275 INDIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 276 INDIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 277 INDIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 278 INDIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 279 INDIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 280 INDIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 281 INDIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 282 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 283 INDIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 284 INDIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 285 INDIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 286 INDIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 287 INDIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 288 INDIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 289 INDIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 290 INDIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 291 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 292 INDIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 293 INDIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 294 INDIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 295 INDIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 296 INDIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 297 INDIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 298 INDIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 299 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 300 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 301 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 302 INDIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 303 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 304 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 305 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 306 INDIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 307 INDIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 308 INDIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 309 INDIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 310 INDIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 311 INDIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 312 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 313 AUSTRALIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 314 AUSTRALIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 315 AUSTRALIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 316 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 317 AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 318 AUSTRALIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 319 AUSTRALIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 320 AUSTRALIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 321 AUSTRALIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 322 AUSTRALIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 323 AUSTRALIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 324 AUSTRALIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 325 AUSTRALIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 326 AUSTRALIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 327 AUSTRALIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 328 AUSTRALIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 329 AUSTRALIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 330 AUSTRALIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 331 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 332 AUSTRALIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 333 AUSTRALIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 334 AUSTRALIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 335 AUSTRALIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 336 AUSTRALIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 337 AUSTRALIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 338 AUSTRALIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 339 AUSTRALIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 340 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 341 AUSTRALIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 342 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 343 AUSTRALIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 344 AUSTRALIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 345 AUSTRALIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 346 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 347 AUSTRALIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 348 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 349 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 350 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 351 AUSTRALIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 352 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 353 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 354 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 355 AUSTRALIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 356 AUSTRALIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 357 AUSTRALIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 358 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 359 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 360 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 361 SINGAPORE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 362 SINGAPORE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 363 SINGAPORE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 364 SINGAPORE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 365 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 366 SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 367 SINGAPORE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 368 SINGAPORE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 369 SINGAPORE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 370 SINGAPORE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 371 SINGAPORE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 372 SINGAPORE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 373 SINGAPORE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 374 SINGAPORE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 375 SINGAPORE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 376 SINGAPORE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 377 SINGAPORE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 378 SINGAPORE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 379 SINGAPORE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 380 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 381 SINGAPORE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 382 SINGAPORE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 383 SINGAPORE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 384 SINGAPORE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 385 SINGAPORE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 386 SINGAPORE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 387 SINGAPORE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 388 SINGAPORE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 389 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 390 SINGAPORE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 391 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 392 SINGAPORE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 393 SINGAPORE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 394 SINGAPORE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 395 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 396 SINGAPORE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 397 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 398 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 399 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 400 SINGAPORE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 401 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 402 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 403 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 404 SINGAPORE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 405 SINGAPORE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 406 SINGAPORE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 407 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 408 SINGAPORE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 409 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 410 THAILAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 411 THAILAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 412 THAILAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 413 THAILAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 414 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 415 THAILAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 416 THAILAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 417 THAILAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 418 THAILAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 419 THAILAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 420 THAILAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 421 THAILAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 422 THAILAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 423 THAILAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 424 THAILAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 425 THAILAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 426 THAILAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 427 THAILAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 428 THAILAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 429 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 430 THAILAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 431 THAILAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 432 THAILAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 433 THAILAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 434 THAILAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 435 THAILAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 436 THAILAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 437 THAILAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 438 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 439 THAILAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 440 THAILAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 441 THAILAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 442 THAILAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 443 THAILAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 444 THAILAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 445 THAILAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 446 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 447 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 448 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 449 THAILAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 450 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 451 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 452 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 453 THAILAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 454 THAILAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 455 THAILAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 456 THAILAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 457 THAILAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 458 THAILAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 459 MALAYSIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 460 MALAYSIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 461 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 462 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 463 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 464 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 465 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 466 MALAYSIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 467 MALAYSIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 468 MALAYSIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 469 MALAYSIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 470 MALAYSIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 471 MALAYSIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 472 MALAYSIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 473 MALAYSIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 474 MALAYSIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 475 MALAYSIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 476 MALAYSIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 477 MALAYSIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 478 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 479 MALAYSIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 480 MALAYSIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 481 MALAYSIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 482 MALAYSIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 483 MALAYSIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 484 MALAYSIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 485 MALAYSIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 486 MALAYSIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 487 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 488 MALAYSIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 489 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 490 MALAYSIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 491 MALAYSIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 492 MALAYSIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 493 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 494 MALAYSIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 495 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 496 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 497 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 498 MALAYSIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 499 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 500 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 501 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 502 MALAYSIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 503 MALAYSIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 504 MALAYSIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 505 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 506 MALAYSIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 507 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 508 INDONESIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 509 INDONESIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 510 INDONESIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 511 INDONESIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 512 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 513 INDONESIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 514 INDONESIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 515 INDONESIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 516 INDONESIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 517 INDONESIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 518 INDONESIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 519 INDONESIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 520 INDONESIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 521 INDONESIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 522 INDONESIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 523 INDONESIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 524 INDONESIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 525 INDONESIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 526 INDONESIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 527 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 528 INDONESIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 529 INDONESIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 530 INDONESIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 531 INDONESIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 532 INDONESIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 533 INDONESIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 534 INDONESIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 535 INDONESIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 536 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 537 INDONESIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 538 INDONESIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 539 INDONESIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 540 INDONESIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 541 INDONESIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 542 INDONESIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 543 INDONESIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 544 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 545 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 546 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 547 INDONESIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 548 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 549 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 550 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 551 INDONESIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 552 INDONESIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 553 INDONESIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 554 INDONESIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 555 INDONESIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 556 INDONESIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 557 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 558 PHILIPPINES INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 559 PHILIPPINES NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 560 PHILIPPINES M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 561 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 562 PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 563 PHILIPPINES REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 564 PHILIPPINES NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 565 PHILIPPINES INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 566 PHILIPPINES NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 567 PHILIPPINES INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 568 PHILIPPINES GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 569 PHILIPPINES PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 570 PHILIPPINES HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 571 PHILIPPINES NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 572 PHILIPPINES NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 573 PHILIPPINES NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 574 PHILIPPINES NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 575 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 576 PHILIPPINES MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 577 PHILIPPINES HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 578 PHILIPPINES DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 579 PHILIPPINES ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 580 PHILIPPINES HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 581 PHILIPPINES VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 582 PHILIPPINES DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 583 PHILIPPINES RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 584 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 585 PHILIPPINES FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 586 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 587 PHILIPPINES GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 588 PHILIPPINES CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 589 PHILIPPINES ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 590 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 591 PHILIPPINES ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 592 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 593 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 594 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 595 PHILIPPINES TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 596 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 597 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 598 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 599 PHILIPPINES PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 600 PHILIPPINES CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 601 PHILIPPINES NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 602 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 603 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 604 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 605 VIETNAM ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 606 VIETNAM INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 607 VIETNAM NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 608 VIETNAM M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 609 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 610 VIETNAM HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 611 VIETNAM REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 612 VIETNAM NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 613 VIETNAM NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 614 VIETNAM INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 615 VIETNAM NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 616 VIETNAM INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 617 VIETNAM GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 618 VIETNAM PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 619 VIETNAM HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 620 VIETNAM NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 621 VIETNAM NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 622 VIETNAM NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 623 VIETNAM NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 624 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 625 VIETNAM MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 626 VIETNAM HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 627 VIETNAM DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 628 VIETNAM ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 629 VIETNAM HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 630 VIETNAM VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 631 VIETNAM DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 632 VIETNAM RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 633 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 634 VIETNAM FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 635 VIETNAM ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 636 VIETNAM GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 637 VIETNAM CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 638 VIETNAM ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 639 VIETNAM ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 640 VIETNAM ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 641 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 642 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 643 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 644 VIETNAM TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 645 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 646 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 647 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 648 VIETNAM PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 649 VIETNAM CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 650 VIETNAM NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 651 VIETNAM ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 652 VIETNAM ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 653 VIETNAM ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 654 REST OF ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 ASIA-PACIFIC ANTIVIRAL DRUGS: SEGMENTATION

FIGURE 2 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF VIRAL INFECTIONS IS EXPECTED TO DRIVE THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET IN THE FORECAST PERIOD

FIGURE 12 THE INFLUENZA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET IN 2023 & 2030

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

FIGURE 16 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , 2022

FIGURE 17 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , 2023-2030 (USD MILLION)

FIGURE 18 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , CAGR (2023-2030)

FIGURE 19 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , LIFELINE CURVE

FIGURE 20 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2022

FIGURE 21 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)

FIGURE 22 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, CAGR (2023-2030)

FIGURE 23 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 24 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2022

FIGURE 25 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 26 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 27 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2022

FIGURE 29 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)

FIGURE 30 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 31 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, 2022

FIGURE 33 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 34 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 35 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 36 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 37 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 38 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 39 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: SNAPSHOT (2022)

FIGURE 41 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022)

FIGURE 42 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 43 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 44 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: INDICATION (2023-2030)

FIGURE 45 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia-Pacific antiviral drugs market size will be worth USD 15,118.64 million by 2030.
The growth rate of the Asia-Pacific antiviral drugs market is 6.7% in the forecast period by the year 2030.
Rising prevalence of viral infections & Advancements in new antiviral drug development are the growth drivers of the Asia-Pacific antiviral drugs market.
Indication, patient type, products, drug type, end user, and distribution channel are the factors on which the Asia-Pacific antiviral drugs market research is based.
Major companies in the Asia-Pacific antiviral drugs market are Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, and Hetero. among others.

관련 페이지 탐색

Banner